4OAS

co-crystal structure of MDM2 (17-111) in complex with compound 25


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.7 Å
  • R-Value Free: 0.239 
  • R-Value Work: 0.214 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2-p53 Inhibitor in Clinical Development.

Sun, D.Li, Z.Rew, Y.Gribble, M.Bartberger, M.D.Beck, H.P.Canon, J.Chen, A.Chen, X.Chow, D.Deignan, J.Duquette, J.Eksterowicz, J.Fisher, B.Fox, B.M.Fu, J.Gonzalez, A.Z.Gonzalez-Lopez De Turiso, F.Houze, J.B.Huang, X.Jiang, M.Jin, L.Kayser, F.Liu, J.J.Lo, M.C.Long, A.M.Lucas, B.McGee, L.R.McIntosh, J.Mihalic, J.Oliner, J.D.Osgood, T.Peterson, M.L.Roveto, P.Saiki, A.Y.Shaffer, P.Toteva, M.Wang, Y.Wang, Y.C.Wortman, S.Yakowec, P.Yan, X.Ye, Q.Yu, D.Yu, M.Zhao, X.Zhou, J.Zhu, J.Olson, S.H.Medina, J.C.

(2014) J.Med.Chem. 57: 1454-1472

  • DOI: 10.1021/jm401753e

  • PubMed Abstract: 
  • We recently reported the discovery of AM-8553 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 interaction. Continued research investigation of the N-alkyl substituent of this series, focused in particular on a previously underutili ...

    We recently reported the discovery of AM-8553 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 interaction. Continued research investigation of the N-alkyl substituent of this series, focused in particular on a previously underutilized interaction in a shallow cleft on the MDM2 surface, led to the discovery of a one-carbon tethered sulfone which gave rise to substantial improvements in biochemical and cellular potency. Further investigation produced AMG 232 (2), which is currently being evaluated in human clinical trials for the treatment of cancer. Compound 2 is an extremely potent MDM2 inhibitor (SPR KD = 0.045 nM, SJSA-1 EdU IC50 = 9.1 nM), with remarkable pharmacokinetic properties and in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft model (ED50 = 9.1 mg/kg).


    Organizational Affiliation

    Departments of Therapeutic Discovery, ‡Pharmaceutics, and §Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California, 94080, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
E3 ubiquitin-protein ligase Mdm2
A, C, E
96Homo sapiensMutation(s): 0 
Gene Names: MDM2
EC: 2.3.2.27
Find proteins for Q00987 (Homo sapiens)
Go to Gene View: MDM2
Go to UniProtKB:  Q00987
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download SDF File 
Download CCD File 
E
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
2SW
Query on 2SW

Download SDF File 
Download CCD File 
A, C, E
[(3R,5R,6S)-1-[(2S)-1-(tert-butylsulfonyl)butan-2-yl]-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl]acetic acid
C28 H35 Cl2 N O5 S
AXQMSOFCQLTJGV-ZJTSJXPUSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
2SWKd: 0 nM (100) BINDINGDB
2SWIC50: 0.1 - 18 nM (100) BINDINGDB
2SWKd: 0.045 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.7 Å
  • R-Value Free: 0.239 
  • R-Value Work: 0.214 
  • Space Group: C 2 2 21
Unit Cell:
Length (Å)Angle (°)
a = 56.554α = 90.00
b = 99.035β = 90.00
c = 107.076γ = 90.00
Software Package:
Software NamePurpose
AMoREphasing
HKL-2000data collection
HKL-2000data reduction
HKL-2000data scaling
CNSrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2014-01-06 
  • Released Date: 2014-02-19 
  • Deposition Author(s): Huang, X.

Revision History 

  • Version 1.0: 2014-02-19
    Type: Initial release
  • Version 1.1: 2014-03-12
    Type: Database references